CD46 activation regulates miR-150-mediated control of GLUT1 expression and cytokine secretion in human CD4+ T cells

Ben C. King, Jonathan L.S. Esguerra, Ewelina Golec, Lena Eliasson, Claudia Kemper, Anna M. Blom*

*Korrespondierende/r Autor/-in für diese Arbeit

Abstract

CD46 is a cell surface complement inhibitor widely expressed in human tissues, in contrast to mice, where expression is limited to the testes. In humans, it has been identified as an important T cell costimulatory receptor, and patients deficient in CD46 or its endogenous ligands are unable to mount effective Th1 T cell responses. Stimulation of human CD4+ T cells with CD3 and CD46 also leads to the differentiation of a "switched" Th1 population, which shuts down IFN-γ secretion and upregulates IL-10 and is thought to be important for negative feedback regulation of the Th1 response. In the present study, we show that CD46 costimulation leads to amplified microRNA (miR) expression changes in human CD4+ T cells, with associated increases in activation more potent than those mediated by the "classic" costimulator CD28. Blockade of cell surface CD46 inhibited CD28-mediated costimulation, identifying autocrine CD46 signaling as downstream of CD28. We also identify a downregulation of miR-150 in CD46-costimulated T cells and identify the glucose transporter 1 encoding transcript SLC2A1 as a target of miR-150 regulation, connecting miR-150 with modulation of glucose uptake. We also investigated microRNA expression profiles of CD46-induced switched IL-10-secreting Th1 T cells and found increased expression of miR-150, compared with IFN-γ-secreting Th1 cells. Knockdown of miR-150 led to a reduction in IL-10 but not IFN-γ. CD46 therefore controls both Th1 activation and regulation via a miR-150-dependent mechanism.

OriginalspracheEnglisch
ZeitschriftJournal of Immunology
Jahrgang196
Ausgabenummer4
Seiten (von - bis)1636-1645
Seitenumfang10
ISSN0022-1767
DOIs
PublikationsstatusVeröffentlicht - 15.02.2016

Fördermittel

This work was supported by Swedish Research Council Projects K2012-66X-14928-09-5 (to A.M.B.) and K2012-55X-13147-14-5 (to L.E.), grants from the Cancerfonden (to A.M.B.), Foundations of ? sterlund (to A.M.B.), the Greta and Johan Kock Foundation (to B.C.K. and A.M.B.), the Gustav V 80 Years Anniversary Foundation (to A.M.B.), the Knut and Alice Wallenberg Foundation (to A.M.B.), and the Inga-Britt and Arne Lundberg Foundation (to A.M.B.), as well as by grants for clinical research from the Ska?ne University Hospital and ALF (to A.M.B.), the Anna-Greta Crafoord Foundation for Rheumatological Research (to B.C.K.), Wellcome Trust Investigator Award (to C.K.), Medical Research Council Grant MR/J006742/1 (to C.K.), and by the European Union?funded Innovative Medicines Initiative Be The Cure (to C.K.). L.E. is a senior researcher at the Swedish Research Council. The work was also funded by the National Institute for Health Research Biomedical Research Centre based at Guy?s and St. Thomas? National Health Service Foundation Trust and King?s College London. We acknowledge the support of the Medical Research Council Centre for Transplantation. We are grateful to Dr. Yvonne Ceder for reagents and advice and to Liza Lind for technical assistance. This work was supported by Swedish Research Council Projects K2012-66X-14928-09-5 (to A.M.B.) and K2012-55X-13147-14-5 (to L.E.), grants from the Cancerfonden (to A.M.B.), Foundations of Ö sterlund (to A.M.B.), the Greta and Johan Kock Foundation (to B.C.K. and A.M.B.), the Gustav V 80 Years Anniversary Foundation (to A.M.B.), the Knut and Alice Wallenberg Foundation (to A.M.B.), and the Inga-Britt and Arne Lundberg Foundation (to A.M.B.), as well as by grants for clinical research from the Ska°ne University Hospital and ALF (to A.M.B.), the Anna-Greta Crafoord Foundation for Rheumatological Research (to B.C.K.), Wellcome Trust Investigator Award (to C.K.), Medical Research Council Grant MR/J006742/1 (to C.K.), and by the European Union–funded Innovative Medicines Initiative Be The Cure (to C.K.). L.E. is a senior researcher at the Swedish Research Council. The work was also funded by the National Institute for Health Research Biomedical Research Centre based at Guy’s and St. Thomas’ National Health Service Foundation Trust and King’s College London. We acknowledge the support of the Medical Research Council Centre for Transplantation. We are grateful to Dr. Yvonne Ceder for reagents and advice and to Liza Lind for technical assistance.

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

  1. SDG 3 – Gesundheit und Wohlergehen
    SDG 3 – Gesundheit und Wohlergehen

Strategische Forschungsbereiche und Zentren

  • Forschungsschwerpunkt: Infektion und Entzündung - Zentrum für Infektions- und Entzündungsforschung Lübeck (ZIEL)

Fingerprint

Untersuchen Sie die Forschungsthemen von „CD46 activation regulates miR-150-mediated control of GLUT1 expression and cytokine secretion in human CD4+ T cells“. Zusammen bilden sie einen einzigartigen Fingerprint.

Zitieren